Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMPNASDAQ:APGNNASDAQ:CYADNASDAQ:MTEM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/ACYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.534.38 million shs3,388 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%APGNApexigen0.00%0.00%0.00%0.00%0.00%CYADCelyad Oncology0.00%0.00%0.00%0.00%0.00%MTEMMolecular Templates0.00%0.00%0.00%-66.67%-99.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPGNApexigenN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/AAPGNApexigen 0.00N/AN/AN/ACYADCelyad Oncology 0.00N/AN/AN/AMTEMMolecular Templates 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00APGNApexigenN/AN/AN/AN/A($0.09) per shareN/ACYADCelyad Oncology$110K144.65N/AN/A$0.26 per share2.31MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AAPGNApexigen-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/ACYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AAPGNApexigenN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19APGNApexigenN/A0.820.82CYADCelyad Oncology0.263.59N/AMTEMMolecular TemplatesN/A1.561.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%APGNApexigen13.65%CYADCelyad OncologyN/AMTEMMolecular Templates95.47%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%APGNApexigen19.20%CYADCelyad Oncology0.94%MTEMMolecular Templates13.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableAPGNApexigen1124.86 million20.09 millionNot OptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataADMP, CYAD, MTEM, and APGN HeadlinesRecent News About These CompaniesMolecular Templates enters bankruptcy, secures DIP financingApril 26, 2025 | investing.comWhat’s Fueling Molecular Templates Inc (MTEM) Stock’s -91.30% Loss Below Its 200-Day SMA?December 26, 2024 | bovnews.comMolecular Templates Inc (MTEM) Stock: More Resilient Than It AppearsDecember 23, 2024 | bovnews.comNasdaq to file Form 25-NSE with SEC to delist Molecular TemplatesDecember 20, 2024 | markets.businessinsider.comMolecular Templates, Inc. Faces Delisting from Nasdaq Due to Compliance IssuesDecember 19, 2024 | quiverquant.comMolecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesDecember 19, 2024 | globenewswire.comMolecular Templates Inc (MTEM) Stock Settles at $0.42: What’s Contributing to This Price Point?December 10, 2024 | bovnews.comMolecular Templates Inc (MTEM) Stock Price Reaches $0.34: What Factors Are Influencing This Level?December 5, 2024 | bovnews.comMolecular Templates Announces Key Leadership TransitionDecember 4, 2024 | markets.businessinsider.comMolecular Templates, Inc. Receives Nasdaq Deficiency Notification for Reporting and Bid Price ComplianceDecember 2, 2024 | quiverquant.comMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsDecember 2, 2024 | globenewswire.comMolecular Templates Inc (MTEM) Stock Settles at $0.37: What’s Contributing to This Price Point?November 29, 2024 | bovnews.comWhy Did BofA Securities Give Molecular Templates Inc (MTEM) Stock Buy Rating?November 27, 2024 | bovnews.comMolecular Templates Inc (MTEM) Stock Sees Market Value Hit $2.21 million: What Are the Implications?November 26, 2024 | bovnews.comMolecular Templates Inc (MTEM) Stock: More Strategic Than Meets the EyeNovember 23, 2024 | bovnews.comTarget N. V. Biotech Sells 1,279,820 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) StockNovember 19, 2024 | insidertrades.comWhy Did Molecular Templates Inc (MTEM) Stock See -69.97% Plunge in the Last 90 Days?November 19, 2024 | bovnews.comMolecular Templates Inc (MTEM) Stock: Surpassing Expectations in the Market?November 16, 2024 | bovnews.com“Astonishing” – Scientists Unveil First Blueprint of the Most Complex Molecular Machine in Human BiologyNovember 10, 2024 | scitechdaily.comWhy Did Molecular Templates Inc (MTEM) Stock See -44.44% Plunge in the Last 90 Days?October 22, 2024 | bovnews.comMedia Sentiment Over TimeADMP, CYAD, MTEM, and APGN Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Apexigen NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Celyad Oncology NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
